PROPRANOLOL IN THE PREVENTION OF THE 1ST HEMORRHAGE FROM ESOPHAGOGASTRIC VARICES - A MULTICENTER, RANDOMIZED CLINICAL-TRIAL

被引:49
作者
CONN, HO
GRACE, ND
BOSCH, J
GROSZMANN, RJ
RODES, J
WRIGHT, SC
MATLOFF, DS
GARCIATSAO, G
FISHER, RL
NAVASA, M
DREWNIAK, SJ
ATTERBURY, CE
BORDAS, JM
LERNER, E
BRAMANTE, C
机构
[1] YALE UNIV,SCH MED,VET ADM MED CTR,MED SERV,W HAVEN,CT 06516
[2] FAULKNER HOSP,DEPT MED,BOSTON,MA 02130
[3] LEMUEL SHATTUCK HOSP,DEPT MED,BOSTON,MA 02130
[4] TUFTS UNIV,SCH MED,BOSTON,MA 02111
[5] HOSP CLIN BARCELONA,DEPT MED,BARCELONA,SPAIN
[6] UNIV BARCELONA,SCH MED,BARCELONA 7,SPAIN
关键词
D O I
10.1016/0270-9139(91)90261-S
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
To assess the effectiveness of propranolol in the prevention of initial variceal hemorrhage, a double-blind, randomized trial was carried out in three centers. Patients with cirrhosis (78% alcoholic), hepatic venous pressure gradients greater than 12 mm Hg and endoscopically proven esophageal varices were randomly assigned to propranolol (51 patients) or placebo (51 patients). Of the 102 patients, 58% were Child's class A, 34% were Child's class B and 8% were Child's class C. Daily dosage was determined by the administration of progressively increasing doses of propranolol with the hepatic vein catheter in place to achieve a 25% decrease in hepatic venous pressure gradient, a decrease in hepatic venous pressure gradient to less than 12 mm Hg or a decrease in resting heart rate to less than 55 beats/min. During a mean follow-up period of 16.3 mo, 11 patients in the placebo group (22%) bled from esophageal varices compared with 2 in the propranolol group (4%) during a mean period of 17.1 mo (p < 0.01). Three additional patients (6%) in the placebo group bled from portal hypertensive gastropathy compared with none in the propranolol group. Propranolol appeared effective in preventing bleeding from large varices. Eleven deaths (22%) occurred in the placebo group compared with eight deaths (16%) in the propranolol group (NS). The mean dose of propranolol was 132 mg/day, and the median dose was 80 mg/day. Using a compliance index (pill count, clinic attendance, alcohol and propranolol levels and alcohol history), 81% of the propranolol patients and 77% of the placebo patients were considered compliant. Complications severe enough to require cessation of therapy occurred in eight patients (16%) in the propranolol group and four in the placebo group (8%) (NS). We conclude that propranolol effectively prevents the first variceal hemorrhage in patients with alcoholic cirrhosis and large esophageal varices but does not improve survival.
引用
收藏
页码:902 / 912
页数:11
相关论文
共 56 条
[31]   A CLINICAL INVESTIGATION OF PORTACAVAL SHUNT .2. SURVIVAL ANALYSIS OF PROPHYLACTIC OPERATION [J].
JACKSON, FC ;
PERRIN, EB ;
SMITH, AG ;
DAGRADI, AE ;
NADAL, HM .
AMERICAN JOURNAL OF SURGERY, 1968, 115 (01) :22-&
[33]   PROPHYLACTIC SCLEROSING OF ESOPHAGEAL-VARICES - RESULTS OF A PROSPECTIVE CONTROLLED-STUDY [J].
KOCH, H ;
HENNING, H ;
GRIMM, H ;
SOEHENDRA, N .
ENDOSCOPY, 1986, 18 (02) :40-43
[34]   A RANDOMIZED CONTROLLED-STUDY OF PROPRANOLOL FOR PREVENTION OF RECURRENT GASTROINTESTINAL-BLEEDING IN PATIENTS WITH CIRRHOSIS - A FINAL REPORT [J].
LEBREC, D ;
POYNARD, T ;
BERNUAU, J ;
BERCOFF, E ;
NOUEL, O ;
CAPRON, JP ;
POUPON, R ;
BOUVRY, M ;
RUEFF, B ;
BENHAMOU, JP .
HEPATOLOGY, 1984, 4 (03) :355-358
[35]   NADOLOL FOR PROPHYLAXIS OF GASTROINTESTINAL-BLEEDING IN PATIENTS WITH CIRRHOSIS - A RANDOMIZED TRIAL [J].
LEBREC, D ;
POYNARD, T ;
CAPRON, JP ;
HILLON, P ;
GEOFFROY, P ;
ROULOT, D ;
CHAPUT, JC ;
RUEFF, B ;
BENHAMOU, JP .
JOURNAL OF HEPATOLOGY, 1988, 7 (01) :118-125
[36]   REDUCTION IN EARLY RECURRENCE OF VARICEAL BLEEDING BY PROPRANOLOL [J].
MARBET, UA ;
STRAUMANN, A ;
GYR, KE ;
BEGLINGER, C ;
SCHAUB, N ;
VOGTLIN, J ;
LOOSLI, J ;
KIOWSKI, W ;
RITZ, R ;
STALDER, GA .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1988, 23 (03) :369-374
[37]  
PAGLIARO L, 1989, GASTROENTEROL INT, V2, P71
[39]   PROPRANOLOL IN THE PREVENTION OF 1ST UPPER GASTROINTESTINAL-TRACT HEMORRHAGE IN PATIENTS WITH CIRRHOSIS OF THE LIVER AND ESOPHAGEAL-VARICES [J].
PASCAL, JP ;
CALES, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (14) :856-861
[40]   PROPHYLACTIC SCLEROTHERAPY OF HIGH-RISK ESOPHAGEAL-VARICES - RESULTS OF A MULTICENTRIC PROSPECTIVE CONTROLLED TRIAL [J].
PIAI, G ;
CIPOLLETTA, L ;
CLAAR, M ;
MARONE, G ;
BIANCO, MA ;
FORTE, G ;
IODICE, G ;
MATTERA, D ;
MINIERI, M ;
ROCCO, P ;
SANTORO, LM ;
MAZZACCA, G .
HEPATOLOGY, 1988, 8 (06) :1495-1500